2027 Request for Proposals: ADDF-Harrington Scholar Program
The ADDF-Harrington Scholar Program funds and supports academic drug development projects with strong clinical potential for Alzheimer’s and related dementias, focusing on novel therapeutic targets beyond amyloid.
Funder: Alzheimer's Drug Discovery Foundation
Due Dates: June 8, 2026: Letter of Intent deadline (extended) | August 17, 2026: Full proposal / Full application deadline
Funding Amounts: Up to $600,000 over 2 years; milestone-driven payments; up to two awards annually.
Summary: Supports academic drug development for Alzheimer’s and related dementias, providing funding and expert guidance for translational projects with clinical potential.
Key Information: For academic investigators in the US, Canada, or UK; anti-amyloid approaches are not supported.
Description
The ADDF-Harrington Scholar Program is a collaboration between the Alzheimer’s Drug Discovery Foundation and the Brain Health Medicines Centers of the Harrington Discovery Institute. Its mission is to accelerate academic discoveries into effective medicines for Alzheimer’s disease and related dementias. The program provides both funding and hands-on project support from industry veterans, focusing on milestone-driven drug development projects with strong translational and clinical promise. High-priority areas include proteostasis, senescence, and other novel therapeutic targets relevant to dementia. Scholars benefit from a tailored team of drug development experts, project management, and business development support, with the goal of delivering lead products with significant clinical and commercial impact.
